Back Hepatitis C

Hepatitis C

EASL 2016: Portugal's Roll-Out of Hepatitis C DAA Therapy Achieves Impressive Outcomes

Roll-out of hepatitis C therapy using direct-acting antivirals (DAAs) has achieved excellent outcomes in Portugal, data presented to the International Liver Congress in Barcelona shows. Overall, 96% of treated patients had a sustained virological response (SVR) to therapy, with a 100% response rate seen in some sub-groups. Treatment also worked well for people with liver cirrhosis and treatment response was unaffected by HIV coinfection, previous hepatitis C therapy, or older age.

alt

EASL 2016: People Treated for Hepatitis C Have Unexpectedly High Rate of Liver Cancer Recurrence

Hepatitis C patients with cirrhosis who were treated with direct-acting antivirals had about twice the expected likelihood of developing hepatocellular carcinoma (HCC), with the excess risk seen in people with a previous history of HCC, according to research presented at the recent European Association for the Study of the Liver's International Liver Congress (EASL 2016) in Barcelona. These findings underline the importance of ongoing liver cancer monitoring even after successful hepatitis C treatment.

alt

EASL 2016: Vaccines for HIV and Hepatitis C Could Potentially Be Administered Together

Immunization against HIV and hepatitis C virus (HCV) could potentially be combined without compromising immune response to either, though effective vaccines for both diseases are still elusive, according to research presented at the European Association for the Study of the Liver's International Liver Congress (EASL 2016) last week in Barcelona.

alt

EASL 2016: AbbVie Pangenotypic Combination Achieves High Cure Rate for Genotype 3 Hepatitis C

A new combination of direct-acting antivirals developed by AbbVie -- ABT493 and ABT-530 -- is highly effective in curing people with genotype 3 hepatitis C virus (HCV) infection and liver cirrhosis, according to results from a pair of Phase 2 studies presented at last week’s EASL International Liver Congress (EASL 2016) in Barcelona.

alt

EASL 2016: Adolescents with Hepatitis C Achieve High Cure Rates with Sofosbuvir/Ledipasvir

Sofosbuvir/ledipasvir (Harvoni) was well-tolerated and led to sustained virological response in 97% of adolescents (age 12-17) with chronic hepatitis C, with high cure rates regardless of prior treatment experience or presence of liver cirrhosis, according to a report presented at the 2016 EASL International Liver Congress in Barcelona.

alt

EASL 2016: DAAs for Hepatitis C Achieve Excellent Outcomes in Real-World Settings

Hepatitis C therapy with direct acting antivirals (DAAs) is as effective in real-world settings as it was in clinical trials, according to U.S. research presented at the International Liver Congress in Barcelona last week. Investigators from the Department of Veteran Affairs (VA) analyzed outcomes in over 9000 patients treated with DAA combinations. Outcomes were excellent, with 2 combinations achieving cure rates of 93%, similar to those seen in randomized studies with strict eligibility criteria and close follow-up.

alt

Coverage of the 2016 EASL International Liver Congress

HIVandHepatitis.com coverage of the 2016 European Association for the Study of the Liver International Liver Congress (EASL 2016) in Barcelona, April 13-17, 2016.

Conference highlights include interferon-free hepatitis C treatment for people with advanced disease, experimental HCV therapy, new treatment for hepatitis B, and management of liver disease complications.

Full listing by topic

International Liver Congress website

4/22/16

alt

EASL 2016: How Generic Direct-Acting Antivirals Are Changing the Hepatitis C Treatment Landscape

The arrival of generic versions of direct-acting antivirals (DAAs) is transforming the global hepatitis C treatment landscape and highlighting the overlooked importance of the cost of monitoring technologies, presenters said at the EASL International Liver Congress (EASL 2016) last week in Barcelona.

alt

EASL 2016: High Incidence of HCV Reinfection Among HIV+ Gay Men in Western Europe

There is a very high incidence of hepatitis C virus (HCV) reinfection among HIV-positive men who have sex with men (MSM) in western Europe, according to research presented at the European Association for the Study of the Liver's International Liver Congress (EASL 2016) this week in Barcelona.  Investigators found that a quarter of HIV-positive gay men who cleared an initial HCV infection were reinfected within 3 years. The researchers believe that current prevention strategies are failing, and called for intensive monitoring of people who have apparently cleared HCV infection.

alt